Syndax Pharmaceuticals (SNDX) Stock Valuation After Positive SAVE Trial Data In High-Risk Leukemia

Simply Wall St.06-15

Syndax Pharmaceuticals (SNDX) stock is back in focus after the company reported Phase 1/2 SAVE trial data for its all-oral Revuforj-based regimen in heavily pretreated acute myeloid leukemia patients ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2643242779?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-06-15 01:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643242779","market":"sg","top_or_hot":-1,"title":"Syndax Pharmaceuticals (SNDX) Stock Valuation After Positive SAVE Trial Data In High-Risk Leukemia","media":"Simply Wall St.","content":"<div>\n<p>Syndax Pharmaceuticals (SNDX) stock is back in focus after the company reported Phase 1/2 SAVE trial data for its all-oral Revuforj-based regimen in heavily pretreated acute myeloid leukemia patients ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-sndx-stock-valuation-after-positive-s\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Syndax Pharmaceuticals (SNDX) Stock Valuation After Positive SAVE Trial Data In High-Risk Leukemia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSyndax Pharmaceuticals (SNDX) Stock Valuation After Positive SAVE Trial Data In High-Risk Leukemia\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-15 01:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-sndx-stock-valuation-after-positive-s><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Syndax Pharmaceuticals (SNDX) stock is back in focus after the company reported Phase 1/2 SAVE trial data for its all-oral Revuforj-based regimen in heavily pretreated acute myeloid leukemia patients ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-sndx-stock-valuation-after-positive-s\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-sndx-stock-valuation-after-positive-s","article_id":"2643242779","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-sndx-stock-valuation-after-positive-s","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2643242779","pubTimestamp":1781457220,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Syndax Pharmaceuticals (SNDX) stock is back in focus after the company reported Phase 1/2 SAVE trial data for its all-oral Revuforj-based regimen in heavily pretreated acute myeloid leukemia patients with high-risk mutations.\nSee our latest analysis for Syndax Pharmaceuticals.\nThe SAVE trial update appears to have given the stock a short-term lift, with a 1-day share price return of 1.9% and 7-day share price return of 5.3%. However, the 90-day share price return is down 24.1%, while the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SNDX":"Syndax Pharmaceuticals, Inc. ","BK4008":"航空公司","BK4500":"航空公司","SAVE":"Spirit Airlines"},"translate_title":"高危白血病SAVE试验数据呈阳性后Syndax Pharmaceuticals(SNDX)股票估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAVE":1.5,"SNDX":1.5},"content_text":"Syndax Pharmaceuticals (SNDX) stock is back in focus after the company reported Phase 1/2 SAVE trial data for its all-oral Revuforj-based regimen in heavily pretreated acute myeloid leukemia patients with high-risk mutations. See our latest analysis for Syndax Pharmaceuticals. The SAVE trial update appears to have given the stock a short-term lift, with a 1-day share price return of 1.9% and 7-day share price return of 5.3%. However, the 90-day share price return is down 24.1%, while the 1-year total shareholder return is 78.1%. This suggests that long-term holders have still seen strong gains despite recent weakness. If this kind of biotech news has your attention, it can be helpful to see what else is moving in related areas by reviewing 40 healthcare AI stocks. So with Syndax now trading at US$18.25, a value score of 4, an intrinsic value estimate implying a large discount, and shares still well below recent 90 day levels, is this a reset the market is mispricing or already factoring in future growth? AdvertisementMost Popular Narrative: 53.8% Undervalued At a last close of $18.25 against a narrative fair value of $39.50, Syndax is framed as heavily discounted, with that gap hinging on a few big clinical and commercial swing factors.  Late-stage pipeline advancements (including frontline trials, lifecycle management, and expansion into new indications like IPF for Niktimvo), coupled with strong clinical data and market-leading positions in precision oncology, provide potential long-term growth avenues. These are aligned with demand for innovative, targeted therapies and support the possibility of multi-year earnings momentum.  Read the complete narrative. Want to see what is built into that growth story? Revenue compounding, margin expansion, and a future earnings profile all factor into this fair value. The key is how quickly those late-stage assets scale, and what profitability looks like if they do. Result: Fair Value of $39.50 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges heavily on Revuforj and Niktimvo, so any clinical or regulatory setback, or slower than expected adoption, could quickly weaken that undervaluation case. Find out about the key risks to this Syndax Pharmaceuticals narrative. Next Steps If this setup feels cautiously optimistic to you, move quickly from headline impressions to the underlying numbers and assess the 2 key rewards. Looking for more investment ideas? If Syndax has sparked your interest, do not stop here. Use the Simply Wall Street Screener to uncover other stocks that might suit your goals and risk comfort.  Target potential mispriced opportunities by scanning 44 high quality undervalued stocks that combine quality fundamentals with attractive valuation signals. Prioritize resilience with 71 resilient stocks with low risk scores if you want companies that score well on stability and downside protection. Spot early-stage prospects before the crowd by reviewing the 24 elite penny stocks with strong financials that still pass solid financial checks.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643242779","isCrawlerRequest":true}